These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11468201)

  • 41. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Goa KL; Noble S
    Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
    Ohman EM; Kleiman NS; Gacioch G; Worley SJ; Navetta FI; Talley JD; Anderson HV; Ellis SG; Cohen MD; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt MM; Sigmon KN; Califf RM; Krucoff MW; Topol EJ
    Circulation; 1997 Feb; 95(4):846-54. PubMed ID: 9054741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
    Madan M; Berkowitz SD; Christie DJ; Jennings LK; Smit AC; Sigmon KN; Glazer S; Tcheng JE
    Am Heart J; 2001 Feb; 141(2):226-33. PubMed ID: 11174336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin.
    Gretler DD
    Clin Ther; 2003 Oct; 25(10):2564-74. PubMed ID: 14667957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.
    Dauerman HL; Ball SA; Goldberg RJ; Desourdy MA; Furman MI
    J Thromb Thrombolysis; 2002 Jun; 13(3):127-32. PubMed ID: 12355028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
    Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE;
    J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.
    Cohen DJ; O'Shea JC; Pacchiana CM; Levine G; Sarembock I; Slater J; Conn E; Smith J; Tcheng JE;
    Am J Cardiol; 2002 Jan; 89(1):61-4. PubMed ID: 11779525
    [No Abstract]   [Full Text] [Related]  

  • 48. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ; Runyon JP; Kleiman NS; Higby NA; Anderson LC; Hantsbarger G; McDonald S; Anders RJ
    Circulation; 1996 Sep; 94(5):906-10. PubMed ID: 8790024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL; Shen S; Guo MM; Zhang GJ; Che J; Wang B; Zhou J
    Pharmazie; 2015 Dec; 70(12):810-4. PubMed ID: 26817279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
    Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
    Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty.
    Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention.
    Mahmud E; Cavendish JJ; Tsimikas S; Ang L; Nguyen C; Bromberg-Marin G; Schnyder G; Keramati S; Palakodeti V; Penny WF; DeMaria AN
    J Am Coll Cardiol; 2007 Jun; 49(22):2163-71. PubMed ID: 17543636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
    Kleiman NS; Tracy RP; Talley JD; Sigmon K; Joseph D; Topol EJ; Califf RM; Kitt M; Ohman EM
    J Thromb Thrombolysis; 2000 Jan; 9(1):5-12. PubMed ID: 10590183
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study.
    Mardikar HM; Hiremath MS; Moliterno DJ; Mathew R; Arora R; Deo D; Hiremath JS; Deshpande NV; Khan A; Joseph J; Mukherjee D
    Am Heart J; 2007 Aug; 154(2):344.e1-5. PubMed ID: 17643586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
    Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
    J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.